No Data
No Data
Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk
Here Are the Top 10 ASX 200 Shares Today
U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk
Will Weakness in Cochlear Limited's (ASX:COH) Stock Prove Temporary Given Strong Fundamentals?
Macquarie Upgrades Cochlear to Neutral From Underperform, Price Target Is AU$289
Cochlear Affirms Up to 11% Underlying Net Profit Growth Guidance for Fiscal 2025
No Data
No Data